Revance Therapeutics, Inc., a clinical stage biotechnology company based in Nashville, Tennessee, specializes in developing and commercializing novel botulinum toxin products for both aesthetic and therapeutic uses. The company, which went public in 2014, offers products like DAXXIFY for aesthetic improvements and is exploring its use in treating muscle movement disorders such as cervical dystonia and upper limb spasticity.
Revance Therapeutics (RVNC) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Revance Therapeutics's actual EPS was -$0.36, beating the estimate of -$0.54 per share, resulting in a 33.41% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
